FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasilington,	D.C.	20040

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

				01.56	ction 30(r	i) or the	invest	ment Co	прап	y Act c	1940						
1. Name and Address of Reporting Person* <u>Mubadala Investment Co PJSC</u>			RE	2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [RXRX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director					
(Last) (First) (Middle) P.O. BOX 45005				3. Date of Earliest Transaction (Month/Day/Year) 01/25/2023								Officer (give title Other (specify below) below)					
(Street) ABU DHABI CO 00000			4. If <i>A</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Parents Reporting					
(City)	(S		(Zip)									Person					
1. Title of Security (Instr. 3) 2. Transaction Date		2. Transaction	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.				red (A) or		5. Amount of Securities Beneficially Owned Following	6. Ownersh Form: Direc (D) or Indirect (I) (Instr. 4)	t Beneficia	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code V		Amount (A		(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)	(1130.4)			
Class A (Common S	tock	01/25/2023			P		24,52	26	A	\$7.8	801(1)	12,346,258	3 I		planation oonses ⁽²⁾	
Class A Common Stock												7,062,869	I	See Explanation of Responses ⁽³⁾			
		Та	ble II - Derivat) e.g., pt											d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Date Execution Date,		4. Transaction Code (Instr. 8) Se Ac (A) Dis of (In an		Exp (Mo	Date Exercisable and piration Date on the piration Date onth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securities Beneficially Owned	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	V (A) (D)	Date Exe	e rcisable	Expii Date	ration	Title	Amour or Number of Shares	er				
1. Name and Address of Reporting Person* Mubadala Investment Co PJSC																	
(Last)	X 45005	(First)	(Middle)		-												
(Street) ABU DI	HABI	C0	00000														
(City)		(State)	(Zip)														
		of Reporting Person rsified Global	* <u>Holding PJS</u>	<u>C</u>													
(Last) P. O. BO	X 45005	(First)	(Middle)														
(Street) ABU DI	HABI	C0	UAE		-												

Explanation of Responses:

(State)

(Zip)

(City)

^{1.} The price reported in Column 4 is a weighted average price. These shares were purchase in multiple transactions at prices ranging from \$7.75 to \$7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4.

^{2.} Consists of 12,346,258 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.

- 3. MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.
- 4. Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
- 5. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Remarks:

6. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.

/s/ Samer Halawa, Chief Legal
Officer, Mubadala Investment
Company PJSC (6)
/s/ Samer Halawa, Chief Legal
Officer, Mamoura Diversified
Global Holdings PJSC (6)

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.